Isis

NASDAQ:ISIS ) , the leader in antisense therapeutics, today announced that management will present a company overview at J.P. Morgan's 28th Annual Healthcare Conference on Wednesday, January 13, 2010, at 9:30 a.m. PT at the Westin St. Francis in San Francisco. Read More

BOTHELL, WA and VANCOUVER, BC , Jan. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding. Read More

Thank you for your recent request for permission to post material by Max Lucado for your group. Read More

If this is the direction Twenty Ten Hip-Hop is going, I'm sure the majority are willing to hop on board. Read More

Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders. Read More

Former ISI chief Hamid Gul has admitted that he played a vital role in the formation of political coalition, the Islami Jamhoori Ittehad (IJI), which was set up in 1988 to oppose the Pakistan Peoples Party in general elections. Read More

The Egyptian goddess Isis was celebrated as the ideal wife and mother. Read More

The Egyptian goddess Isis was celebrated as the ideal wife and mother. Read More

The Egyptian goddess Isis was celebrated as the ideal wife and mother. Read More

Director, COO of Isis Pharmaceuticals Inc. (ISIS) B Lynne Parshall sells 7,090 shares of ISIS on 12/31/2009 at an average price of $11.21 a share. Read More